A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Condition: Follicular Lymphoma (FL) Interventions: Biological: Tisagenlecleucel; Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.; Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles; Drug: Lymphodepleting chemotherapy; Ot her: Corticosteroids and/or Radiation (Bridging therapy) Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Condition: Diffuse Large B Cell Lymphoma Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone Sponsor: Liaoning Tumor Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Condition: Follicular Lymphoma (FL) Interventions: Biological: Tisagenlecleucel; Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.; Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles; Drug: Lymphodepleting chemotherapy; Ot her: Corticosteroids and/or Radiation (Bridging therapy) Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Condition: Diffuse Large B Cell Lymphoma Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone Sponsor: Liaoning Tumor Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Condition: Follicular Lymphoma (FL) Interventions: Biological: Tisagenlecleucel; Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.; Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles; Drug: Lymphodepleting chemotherapy; Ot her: Corticosteroids and/or Radiation (Bridging therapy) Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Condition: Diffuse Large B Cell Lymphoma Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone Sponsor: Liaoning Tumor Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Condition: Follicular Lymphoma (FL) Interventions: Biological: Tisagenlecleucel; Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.; Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles; Drug: Lymphodepleting chemotherapy; Ot her: Corticosteroids and/or Radiation (Bridging therapy) Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Condition: Diffuse Large B Cell Lymphoma Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone Sponsor: Liaoning Tumor Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Condition: Follicular Lymphoma (FL) Interventions: Biological: Tisagenlecleucel; Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.; Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles; Drug: Lymphodepleting chemotherapy; Ot her: Corticosteroids and/or Radiation (Bridging therapy) Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Condition: Diffuse Large B Cell Lymphoma Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone Sponsor: Liaoning Tumor Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Condition: Follicular Lymphoma (FL) Interventions: Biological: Tisagenlecleucel; Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.; Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles; Drug: Lymphodepleting chemotherapy; Ot her: Corticosteroids and/or Radiation (Bridging therapy) Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors
Condition: Diffuse Large B Cell Lymphoma Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone Sponsor: Liaoning Tumor Hospital & Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Condition: Follicular Lymphoma (FL) Interventions: Biological: Tisagenlecleucel; Drug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.; Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles; Drug: Lymphodepleting chemotherapy; Ot her: Corticosteroids and/or Radiation (Bridging therapy) Sponsor: Novartis Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 5, 2023 Category: Research Source Type: clinical trials
